Shea T C, Claflin G, Comstock K E, Sanderson B J, Burstein N A, Keenan E J, Mannervik B, Henner W D
Department of Medicine, University of California, San Diego.
Cancer Res. 1990 Nov 1;50(21):6848-53.
The human glutathione transferases (GSTs) are a multigene family of detoxication enzymes with patterns of expression that are both tissue specific and genetically determined. Changes in the levels of one or more GST isoenzymes have been associated with the development of anticancer drug resistance in cultured cell lines. In this study, total GST activity and GST isoenzyme composition have been determined for 45 primary human breast carcinomas using a 1-chloro-2,4-dinitrobenzene substrate assay and Western blotting, respectively. The GST activity ranged from 5-208 mU/mg protein with a mean of 67 mU/mg protein (+/- 44 SD). GST-pi) isoenzyme protein was detectable on Western blots in 44 of 45 samples. Mu Class GST protein was detected in 18 of 38 samples and undetectable in 20 of the 38 samples tested. By polymerase chain reaction analysis of genomic DNA, the absence of mu class GST in breast tumors was determined to be due to the deletion of the gene for GST-mu in the DNA of those tumors. None of the 43 primary human breast cancer samples tested contained detectable alpha class GST protein. Neither the total GST activity of tumor samples, the quantity of GST-pi protein, nor the presence or absence of mu class GST correlated with other factors known to be of prognostic significance including tumor size, nodal status, estrogen receptor protein positivity, or progesterone receptor protein positivity. Substantial differences exist among primary breast carcinomas in both the amount of GST activity and GST isoenzyme composition. However, these are not tightly linked either to tumor stage or to hormone receptor status. Whether the levels of these enzymes are independent predictors of either risk of recurrence or response to anticancer therapy has yet to be tested directly.
人类谷胱甘肽转移酶(GSTs)是一个解毒酶的多基因家族,其表达模式具有组织特异性且由基因决定。一种或多种GST同工酶水平的变化与培养细胞系中抗癌药物耐药性的发展有关。在本研究中,分别使用1-氯-2,4-二硝基苯底物测定法和蛋白质印迹法,对45例原发性人类乳腺癌的总GST活性和GST同工酶组成进行了测定。GST活性范围为5 - 208 mU/mg蛋白质,平均为67 mU/mg蛋白质(±44 SD)。在45个样本中的44个样本的蛋白质印迹上可检测到GST-π同工酶蛋白。在38个样本中的18个样本中检测到μ类GST蛋白,在38个测试样本中的20个样本中未检测到。通过对基因组DNA的聚合酶链反应分析,确定乳腺肿瘤中μ类GST的缺失是由于这些肿瘤DNA中GST-μ基因的缺失。在43例原发性人类乳腺癌样本中,无一检测到可检测的α类GST蛋白。肿瘤样本的总GST活性、GST-π蛋白的量,以及μ类GST的存在与否,均与已知具有预后意义的其他因素无关,包括肿瘤大小、淋巴结状态、雌激素受体蛋白阳性或孕激素受体蛋白阳性。原发性乳腺癌在GST活性量和GST同工酶组成方面存在显著差异。然而,这些差异与肿瘤分期或激素受体状态均无紧密联系。这些酶的水平是否是复发风险或抗癌治疗反应的独立预测指标,还有待直接检验。